BrainStorm hits record low after FDA panel votes against co's ALS therapy

Brainstorm Cell Therapeutics

28/09/2023 14:49

(Updates)
    ** BrainStorm Cell Therapeutics  BCLI.O  shares fall ~55% to
17 cents 
    ** Advisers to the U.S. FDA on Wednesday voted against co's
therapy NurOwn for a rare and fatal neurodegenerative disease
called amyotrophic lateral sclerosis (ALS)
    ** 17 FDA members voted that the therapy has not
demonstrated enough evidence of effectiveness, while one member
voted in favour and one abstained 
    ** FDA is expected to make a decision on the drug by Dec. 8
    ** Up to last close, shares down 76% YTD 

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))